DalsnaFinance

VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis

Markets PR Newswire By PR Newswire 05 Jun 2026 13:00 1 min read
VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis

BEVERLY, Mass., June 5, 2026 /PRNewswire/ -- Today at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine, VetrixBio (www.vetrixbio.com) presented the first clinical data for VTX-304, its investigational bispecific antibody designed to...

BEVERLY, Mass., June 5, 2026 /PRNewswire/ -- Today at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine, VetrixBio (www.vetrixbio.com) presented the first clinical data for VTX-304, its investigational bispecific antibody designed to...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.